Dynamic Changes of Tumor-infiltrating Immune Cells in Mice with MC38 Colon Cancer

doi:10.12300/j.issn.1674-5817.2020.157

Abstract

Abstract: Objective To observe the dynamic changes of tumor-infiltrating immune cells in tumor-bearing mice during tumor development. Methods Mouse colon cancer MC38 cells were transplanted subcutaneously into 24 C57BL/6J mice, and the changes in body mass and tumor size of mice were recorded once a week after tumor-bearing, The levels of tumor-infiltrating immune cells, including CD45⁺ T cells, CD3⁺ T cells, CD8⁺ T cells, CD4⁺ T cells, natural killer (NK) cells, dendritic cells, macrophages, M1-type macrophages, M2-type macrophages, myeloid-derived suppressor cells (MDSCs), mononuclear-like MDSCs (M-MDSCs), and granulocytic MDSCs (G-MDSCs) were detected by flow cytometry once a week for 4 weeks. Results As the colon cancer tumor of the mouse grows, total CD45⁺ T cellular level decreased, and CD8⁺ T cellular level steadily decreased to an irreversible level, but CD4⁺ T cells proportion rapidly increased at the early stage of the tumor-bearing, quantity of infiltrating cells in the unit volume increased by 8 times, and T cells of tumor-infiltration almost were CD4⁺ phenotype. The nonspecific immune response level represented by NK cells continued to decline, but the dendritic cells continued to accumulate in the tumor. The immunosuppressive action was further enhanced through the activation of arginase-1 (ARG1) and inducible nitric oxide synthetase (iNOS). Macrophage infiltration levels showed no significant change, but the gliding speed for the quantity of infiltrating type-Ⅰ macrophages was obviously higher than that of type-Ⅱ macrophages. The proportion of MDSCs per unit volume showed no decreasing trend, and the cells continued to accumulate in the tumor. G-MDSC infiltration level showed a steady decrease, while M-MDSC infiltration level showed an increasing trend, the proportion of M-MDSCs were higher than that of G-MDSCs. Conclusion After transplanting MC38 colon cancer cells in mice, the level of immune cell infiltration in the tumor tissue declined, tumor immunology gradually became dominat, thus promoting the development of colon cancer. The Th1/Th2 drift occurred in the tumor. Specific and nonspecific immune response levels were significantly decreased on an average, and the infiltrating monocytes and granulocytes were mainly Ly6C⁺. Tumor-associated dendritic cells and macrophages play an important immunosuppressive role. CD4⁺T cells and M-MDSCs might be the key for promoting tumor immunity.

Key words: Colon cancer, Tumor-infiltrating immune cells, Tumor immune microenvironment, Mice

CLC Number:

Q95-33
R-332

ZHANG Boyang, CHEN Huanpeng, YU Wenlan, LIU Zhonghua, HUANG Chaofeng. Dynamic Changes of Tumor-infiltrating Immune Cells in Mice with MC38 Colon Cancer[J]. Laboratory Animal and Comparative Medicine, 2021, 41(5): 409-417.

Figures/Tables 5

References

[1] ENGBLOM C, PFIRSCHKE C, PITTET M J.The role of myeloid cells in cancer therapies[J]. Nat Rev Cancer, 2016, 16(7):447-462. DOI:10.1038/nrc.2016.54.
[2] HUI L, CHEN Y.Tumor microenvironment: Sanctuary of the devil[J]. Cancer Lett, 2015, 368(1):7-13. DOI:10.1016/j.canlet.2015.07.039.
[3] MIYASHITA M, SASANO H, TAMAKI K, et al.Prognostic significance of tumor-infiltrating CD8+ and FOXP3+ lymphocytes in residual tumors and alterations in these parameters after neoadjuvant chemotherapy in triple-negative breast cancer: a retrospective multicenter study[J]. Breast Cancer Res, 2015, 17:124. DOI:10.1186/s13058-015-0632-x.
[4] FENG W, LI Y, SHEN L, et al.Prognostic value of tumor-infiltrating lymphocytes for patients with completely resected stage IIIA(N₂) non-small cell lung cancer[J]. Oncotarget, 2016, 7(6):7227-7240. DOI:10.18632/oncotarget.6979.
[5] DE PALMA M, BIZIATO D, PETROVA T V.Microenvironmental regulation of tumour angiogenesis[J]. Nat Rev Cancer, 2017, 17(8):457-474. DOI:10.1038/nrc.2017.51.
[6] BINDEA G, MLECNIK B, TOSOLINI M, et al.Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer[J]. Immunity, 2013, 39(4):782-795. DOI:10.1016/j.immuni.2013.10.003.
[7] PAGÈS F, BERGER A, CAMUS M, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer[J]. N Engl J Med, 2005, 353(25):2654-2666. DOI:10.1056/nejmoa051424.
[8] ATREYA I, NEURATH M F.Immune cells in colorectal cancer: prognostic relevance and therapeutic strategies[J]. Expert Rev Anticancer Ther, 2008, 8(4):561-572. DOI:10.1586/14737140.8.4.561.
[9] BINDEA G, MLECNIK B, FRIDMAN W H, et al.Natural immunity to cancer in humans[J]. Curr Opin Immunol, 2010, 22(2):215-222. DOI:10.1016/j.coi.2010.02.006.
[10] PAGÈS F, KIRILOVSKY A, MLECNIK B, et al. In situ cytotoxic and memory T cells predict outcome in patients with early-stage colorectal cancer[J]. J Clin Oncol, 2009, 27(35):5944-5951. DOI:10.1200/jco.2008.19.6147.
[11] LESTERHUIS W J, BOSCO A, MILLWARD M J, et al.Dynamic versus static biomarkers in cancer immune checkpoint blockade: unravelling complexity[J]. Nat Rev Drug Discov, 2017, 16(4):264-272. DOI:10.1038/nrd.2016.233.
[12] SHARMA P, WAGNER K, WOLCHOK J D, et al.Novel cancer immunotherapy agents with survival benefit: recent successes and next steps[J]. Nat Rev Cancer, 2011, 11(11):805-812. DOI:10.1038/nrc3153.
[13] LAUEROVA L, DUSEK L, SIMICKOVA M, et al.Malignant melanoma associates with Th1/Th2 imbalance that coincides with disease progression and immunotherapy response[J]. Neoplasma, 2002, 49(3):159-166.
[14] HANAHAN D, WEINBERG R A.Hallmarks of cancer: the next generation[J]. Cell, 2011, 144(5):646-674. DOI:10.1016/j.cell.2011.02.013.
[15] 焦国慧, 杨荣存. 肿瘤相关免疫抑制细胞与免疫逃逸机制研究进展[J]. 癌症进展, 2008, 6(2):147-151. DOI:10.3969/j.issn.1672-1535.2008.02.009.
[16] DENARDO D G, RUFFELL B.Macrophages as regulators of tumour immunity and immunotherapy[J]. Nat Rev Immunol, 2019, 19(6):369-382. DOI:10.1038/s41577-019-0127-6.
[17] MARVEL D, GABRILOVICH D I.Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected[J]. J Clin Invest, 2015, 125(9):3356-3364. DOI:10.1172/jci80005.